Zydus Lifesciences
BSE: 532321 | NSE: ZYDUSLIFE | ISIN: INE010B01027 | SECTOR: Biotechnology & DrugsOpen
929.30High
933.00Low
914.05Prev Close
936.30P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
923.32BVolume
27.39KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
917.40Ask
917.90
Company Description
- Biotechnology & Drugs
BSE
532321NSE
ZYDUSLIFEISIN
INE010B01027
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Company Officers
Nitin Parekh
Chief Financial OfficerDhaval Soni
Company Secretary, Chief Compliance OfficerSharvil Patel
Managing Director, Executive DirectorGanesh Nayak
Executive Director